# 産婦人科

## 投与間隔　：　7　日

| レジメン名 | 商品名 | 剤形 | 投与量 | スケジュール　（日） | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| **CDDP+RT** | シスプラチン | 注 | 40　mg/m$^2$ | ○ | | | | | | |
| | 備考 | | | | | | | | | |
| **MTX筋注** | メソトレキサート | 注 | 50　mg | ○ | | | | | | |
| | 備考 | | | | | | | | | |
| **アクプラ＋RT** | アクプラ | 注 | 30　mg/m$^2$ | ○ | | | | | | |
| | 備考 | | | | | | | | | |

## 投与間隔　：　14　日

| レジメン名 | 商品名 | 剤形 | 投与量 | スケジュール　（日） | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 |
| **MTX筋注（絨毛性疾患）** | メソトレキサート | 注 | 0.4　mg/kg | ○ | ○ | ○ | ○ | ○ | | | | | | | | | |
| | 備考 | | | | | | | | | | | | | | | | |

## 投与間隔　：　21　日

| レジメン名 | 商品名 | 剤形 | 投与量 | スケジュール　（日） | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 |
| **AP** | ドキソルビシン | 注 | 60　mg/m$^2$ | ○ | | | | | | | | | | | | | | | | | | | | |
| | シスプラチン | 注 | 50　mg/m$^2$ | ○ | | | | | | | | | | | | | | | | | | | | |
| | 備考 | | | | | | | | | | | | | | | | | | | | | | | |
| **Bev（維持）** | アバスチン | 注 | 15　mg/kg | ○ | | | | | | | | | | | | | | | | | | | | |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Bev（継続） | 備考 | | | | | | |
| Bev+DC | アバスチン | 注 | 15 | mg/kg | ○ | | |
| | ドセタキセル | 注 | 60 | mg/m$^2$ | ○ | | |
| | カルボプラチン | 注 | 5 | AUC | ○ | | |
| | 備考 | | | | | | |
| Bev+GEM+CBDCA | アバスチン | 注 | 15 | mg/kg | ○ | | |
| | ゲムシタビン | 注 | 1000 | mg/m$^2$ | ○ | ○ | |
| | カルボプラチン | 注 | 4 | AUC | ○ | | |
| | 備考 | | | | | | |
| Bev+PTX | アバスチン | 注 | 15 | mg/kg | ○ | | |
| | パクリタキセル | 注 | 80 | mg/m$^2$ | ○ | ○ | ○ |
| | 備考 | | | | | | |
| Bev+TC | アバスチン | 注 | 15 | mg/kg | ○ | | |
| | パクリタキセル | 注 | 175 | mg/m$^2$ | ○ | | |
| | カルボプラチン | 注 | 6 | AUC | ○ | | |
| | 備考 | | | | | | |
| Bev+TP | アバスチン | 注 | 15 | mg/kg | ○ | | |
| | パクリタキセル | 注 | 175 | mg/m$^2$ | ○ | | |
| | シスプラチン | 注 | 70 | mg/m$^2$ | ○ | | |
| | 備考 | | | | | | |
| DC | ドセタキセル | 注 | 60 | mg/m$^2$ | ○ | | |
| | カルボプラチン | 注 | 5 | AUC | ○ | | |
| | 備考 | | | | | | |
| GEM+CBDCA | ゲムシタビン | 注 | 1000 | mg/m$^2$ | ○ | ○ | |
| | カルボプラチン | 注 | 4 | AUC | ○ | | |
| | 備考 | | | | | | |
| ddTC | パクリタキセル | 注 | 80 | mg/m$^2$ | ○ | ○ | ○ |
| | カルボプラチン | 注 | 6 | AUC | ○ | | |

| | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | 備考 | | | | | | | | | | | | | | | | | | | | | | | | |
| **TC** | パクリタキセル | 注 | 175 | $mg/m^2$ | ○ | | | | | | | | | | | | | | | | | | | | |
| | カルボプラチン | 注 | 6 | AUC | ○ | | | | | | | | | | | | | | | | | | | | |
| | 備考 | | | | | | | | | | | | | | | | | | | | | | | | |
| **TP** | パクリタキセル | 注 | 175 | $mg/m^2$ | ○ | | | | | | | | | | | | | | | | | | | | |
| | シスプラチン | 注 | 70 | $mg/m^2$ | ○ | | | | | | | | | | | | | | | | | | | | |
| | 備考 | | | | | | | | | | | | | | | | | | | | | | | | |
| **DP** | ドセタキセル | 注 | 70 | $mg/m^2$ | ○ | | | | | | | | | | | | | | | | | | | | |
| | シスプラチン | 注 | 60 | $mg/m^2$ | ○ | | | | | | | | | | | | | | | | | | | | |
| | 備考 | | | | | | | | | | | | | | | | | | | | | | | | |
| **CBDCA単剤** | カルボプラチン | 注 | 6 | AUC | ○ | | | | | | | | | | | | | | | | | | | | |
| | 備考 | | | | | | | | | | | | | | | | | | | | | | | | |
| **CDDP単剤** | シスプラチン | 注 | 70 | $mg/m^2$ | ○ | | | | | | | | | | | | | | | | | | | | |
| | 備考 | | | | | | | | | | | | | | | | | | | | | | | | |
| **ドキソルビシン単剤** | ドキソルビシン | 注 | 50 | $mg/m^2$ | ○ | | | | | | | | | | | | | | | | | | | | |
| | 備考 | | | | | | | | | | | | | | | | | | | | | | | | |
| **アクプラ単剤** | アクプラ | 注 | 80 | $mg/m^2$ | ○ | | | | | | | | | | | | | | | | | | | | |
| | 備考 | | | | | | | | | | | | | | | | | | | | | | | | |
| **DOC+GEM（肉腫）** | ドセタキセル | 注 | 60 | $mg/m^2$ | | | | | | | | ○ | | | | | | | | | | | | | |
| | ゲムシタビン | 注 | 800 | $mg/m^2$ | ○ | | | | | | | ○ | | | | | | | | | | | | | |
| | 備考 | | | | | | | | | | | | | | | | | | | | | | | | |
| **BEP** | ブレオ | 注 | 20 | $mg/m^2$ | | ○ | | | | | | | ○ | | | | | | | ○ | | | | | |
| | エトポシド | 注 | 100 | $mg/m^2$ | ○ | ○ | ○ | ○ | ○ | | | | | | | | | | | | | | | | |
| | シスプラチン | 注 | 20 | $mg/m^2$ | ○ | ○ | ○ | ○ | ○ | | | | | | | | | | | | | | | | |
| | 備考 | | | | | | | | | | | | | | | | | | | | | | | | |
| **Bev+GEM** | アバスチン | 注 | 15 | mg/kg | ○ | | | | | | | | | | | | | | | | | | | | |
| | ゲムシタビン | 注 | 1000 | $mg/m^2$ | ○ | | | | | | | ○ | | | | | | | | | | | | | |
| | 備考 | | | | | | | | | | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **キイトルーダ（3週毎）** | キイトルーダ | 注 | 200 | mg | ○ | | | | | | | | | | | | | | | | | | | | |
| | 備考 | MSI-High固形癌 | | | | | | | | | | | | | | | | | | | | | | | |
| **Bev+リムパーザ（維持）** | アバスチン | 注 | 15 | mg/kg | ○ | | | | | | | | | | | | | | | | | | | | |
| | リムパーザ | 内服 | 200-300(mg)/回 | 朝 | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| | | | | 夕 | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| | 備考 | | | | | | | | | | | | | | | | | | | | | | | | |

## 投与間隔　：　28　日

| レジメン名 | 商品名 | 剤形 | 投与量 | | スケジュール　（日） | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 |
| **Bev+ドキシル** | アバスチン | 注 | 15 | mg/kg | ○ | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | ドキシル | 注 | 40 | mg/m² | ○ | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 備考 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| **GEM** | ゲムシタビン | 注 | 800 | mg/m² | ○ | | | | | | | ○ | | | | | | | ○ | | | | | | | | | | | | | |
| | 備考 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| **ドキシル+CBDCA** | ドキシル | 注 | 30 | mg/m² | ○ | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | カルボプラチン | 注 | 5 | AUC | ○ | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 備考 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| **ドキシル単剤** | ドキシル | 注 | 40 | mg/m² | ○ | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 備考 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| **CPT-11単剤** | イリノテカン | 注 | 100 | mg/m² | ○ | | | | | | | ○ | | | | | | | ○ | | | | | | | | | | | | | |
| | 備考 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| **PTX Weekly** | パクリタキセル | 注 | 80 | mg/m² | ○ | | | | | | | ○ | | | | | | | ○ | | | | | | | | | | | | | |
| | 備考 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| **CPT-11 Biweekly** | イリノテカン | 注 | 150 | mg/m² | ○ | | | | | | | | | | | | | | ○ | | | | | | | | | | | | | |
| | 備考 | 子宮頸癌専用レジメン | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |